Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time
10 mai 2021 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has launched a new, four-hour Acute Myeloid Leukemia (AML)...
Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel
22 sept. 2020 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ AML (Acute Myeloid...